SWTX SpringWorks Therapeutics, Inc.

Nasdaq springworkstx.com


$ 46.99 $ 0.01 (0.02 %)    

Monday, 30-Jun-2025 16:31:18 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 46.99
$ 46.99
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 28.21 - $ 62.00
5,010,844
na
3.54B
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2025 03-31-2025 10-Q
2 02-20-2025 12-31-2024 10-K
3 11-12-2024 09-30-2024 10-Q
4 08-07-2024 06-30-2024 10-Q
5 05-02-2024 03-31-2024 10-Q
6 02-27-2024 12-31-2023 10-K
7 11-02-2023 09-30-2023 10-Q
8 08-02-2023 06-30-2023 10-Q
9 05-03-2023 03-31-2023 10-Q
10 02-28-2023 12-31-2022 10-K
11 11-03-2022 09-30-2022 10-Q
12 08-04-2022 06-30-2022 10-Q
13 05-05-2022 03-31-2022 10-Q
14 02-24-2022 12-31-2021 10-K
15 11-04-2021 09-30-2021 10-Q
16 08-04-2021 06-30-2021 10-Q
17 05-05-2021 03-31-2021 10-Q
18 02-25-2021 12-31-2020 10-K
19 11-12-2020 09-30-2020 10-Q
20 08-12-2020 06-30-2020 10-Q
21 05-12-2020 03-31-2020 10-Q
22 03-12-2020 12-31-2019 10-K
23 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 legendary-investor-stanley-druckenmiller-made-huge-ai-and-chipmaker-bets-in-q2--heres-what-he-knows-that-you-dont

See Stanley Druckenmiller's Q2 13F filing. Duquesne adds Microsoft and big banks, cuts Coupang, and makes a bullish bet on ...

 springworks-therapeutics-receives-ec-conditional-marketing-approval-for-ezmekly-in-treating-nf1-pn-across-pediatric-and-adult-patients

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commi...

 springworks-therapeutics-secures-ema-chmp-endorsement-for-conditional-approval-of-mirdametinib-in-nf1-pn-treatment

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for...

 guggenheim-reiterates-neutral-on-springworks-therapeutics-maintains-47-price-target

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Neutral and maintains $47 price ...

 hc-wainwright--co-downgrades-springworks-therapeutics-to-neutral-lowers-price-target-to-47

HC Wainwright & Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lower...

 correction-guggenheim-downgrades-springworks-therapeutics-to-neutral-lowers-price-target-to-47-firm-change-from-stephens--co-to-guggenheim

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers...

 td-cowen-downgrades-springworks-therapeutics-to-hold-lowers-price-target-to-47

TD Cowen analyst Yaron Werber downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Hold and lowers the price target...

 barclays-downgrades-springworks-therapeutics-to-equal-weight-lowers-price-target-to-47

Barclays analyst Peter Lawson downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Overweight to Equal-Weight and lowers t...

 merck-germany-buys-us-cancer-drugmaker-springworks-therapeutics-for-around-4-billion

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

Core News & Articles

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3....

 germanys-merck-nears-roughly-35-billion-deal-for-springworks-merck-and-springworks-have-agreed-on-a-price-close-to-47-per-share---wsj

https://www.wsj.com/business/deals/germanys-merck-nears-roughly-3-5-billion-deal-for-springworks-2c7258b9

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION